secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-004104
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics reports FY2022 net loss $20.3M; cash $18.1M; CPRIT grant $17.6M
--------------------------------------------------------------------------------

- Net loss $20.3M ($0.77/share) vs $13.4M ($1.11/share) in FY2021; operating expenses $19.9M.
- Cash $18.1M at Dec 31, 2022; with grants and capital sources, expects funding through 2025.
- Awarded $17.6M CPRIT grant for rhenium obisbemeda leptomeningeal metastases trial.
- Enrolled first patient in ReSPECT-GBM Phase 2b; completed second cohort in ReSPECT-LM Phase 1.
- Grant revenue $224k from CPRIT; received first ~$1.9M in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/0000950170-23-004104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/pstv-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer